Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 10,000 Shares

Key Points

• Jonathan Allan, General Counsel of Stoke Therapeutics, sold 10,000 shares for approximately $250,700, reducing his stake by 45.81%.
• Stoke Therapeutics reported a quarterly loss of ($0.40) earnings per share, better than analysts' expectations of ($0.57), with revenues of $13.82 million.
• Multiple firms, including Jefferies and Chardan Capital, have issued buy ratings on Stoke Therapeutics, with target prices ranging from $22.00 to $30.00.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 10,000 shares of the stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $25.07, for a total transaction of $250,700.00. Following the transaction, the general counsel owned 11,831 shares of the company's stock, valued at $296,603.17. This trade represents a 45.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jonathan Allan also recently made the following trade(s):

• On Wednesday, September 3rd, Jonathan Allan sold 6,345 shares of Stoke Therapeutics stock. The shares were sold at an average price of $20.07, for a total value of $127,344.15.
• On Tuesday, September 2nd, Jonathan Allan sold 14,922 shares of Stoke Therapeutics stock. The stock was sold at an average price of $20.14, for a total transaction of $300,529.08.
• On Friday, August 29th, Jonathan Allan sold 850 shares of Stoke Therapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $17,000.00.
• On Wednesday, August 13th, Jonathan Allan sold 13,712 shares of Stoke Therapeutics stock. The stock was sold at an average price of $15.00, for a total transaction of $205,680.00.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock traded up $0.50 during midday trading on Tuesday, reaching $27.31. The company had a trading volume of 859,765 shares, compared to its average volume of 835,877. Stoke Therapeutics, Inc. has a 12-month low of $5.35 and a 12-month high of $28.00. The firm's fifty day simple moving average is $19.64 and its 200-day simple moving average is $13.31. The company has a market capitalization of $1.50 billion, a P/E ratio of 32.13 and a beta of 1.24.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. The firm had revenue of $13.82 million during the quarter, compared to analysts' expectations of $31.51 million. On average, analysts expect that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on STOK. Jefferies Financial Group assumed coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They set a "buy" rating and a $30.00 target price on the stock. Chardan Capital reiterated a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Weiss Ratings restated a "sell (d+)" rating on shares of Stoke Therapeutics in a report on Saturday, September 27th. BTIG Research set a $28.00 price objective on Stoke Therapeutics and gave the company a "buy" rating in a research note on Monday, August 18th. Finally, Needham & Company LLC restated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Stoke Therapeutics has an average rating of "Buy" and a consensus target price of $25.57.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Siren L.L.C. lifted its holdings in shares of Stoke Therapeutics by 12.4% during the first quarter. Siren L.L.C. now owns 2,247,347 shares of the company's stock worth $14,945,000 after purchasing an additional 247,347 shares during the period. GAMMA Investing LLC raised its position in Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after buying an additional 5,084 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company's stock worth $1,053,000 after acquiring an additional 52,813 shares during the period. Invesco Ltd. lifted its stake in shares of Stoke Therapeutics by 117.0% in the 1st quarter. Invesco Ltd. now owns 26,183 shares of the company's stock worth $174,000 after acquiring an additional 14,118 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Stoke Therapeutics in the first quarter valued at about $2,376,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.